Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b vehicle-controlled, double-blind, multicenter study assessing ARQ-255 in healthy adult volunteers and individuals with patchy alopecia areata

Next Previous
Search
Trial Profile

A Phase 1b vehicle-controlled, double-blind, multicenter study assessing ARQ-255 in healthy adult volunteers and individuals with patchy alopecia areata

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ARQ 252 (Primary)
  • Indications Alopecia areata
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
  • Sponsors Arcutis Biotherapeutics

    • Most Recent Events

    • 05 Sep 2024 Status changed from recruiting to active, no longer recruiting, according to an Arcutis Biotherapeutics media release.
    • 05 Sep 2024 According to an Arcutis Biotherapeutics media release, company announced the enrollment of the last subject in this Phase 1b study assessing ARQ-255, a topical suspension of ivarmacitinib, for the treatment of alopecia areata. Results from the study are expected to be reported in the first half of 2025.
    • 08 Aug 2023 According to Arcutis Biotherapeutics media release, the first subject in the alopecia areata cohort enrolled in the second quarter of 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top